Respiratory syncytial virus (RSV), a single-stranded RNA virus of the Paramyxoviridae family, is a major cause of bronchiolitis in infants and is also conjectured to be an early-life influence on the development of asthma. Although the data supporting a role for RSV in bronchiolitis in children are robust and evidence to support its role in juvenile asthmatics exists, RSV's role in asthma pathogenesis in adults is not as clearly defined. The authors review the literature to further elucidate RSV's impact on adult asthmatics, including its importance as a cause of asthma exacerbations. They examine the morbidity associated with RSV infection and how the immune response may differ between adult asthmatics and nonasthmatics. They review the responses by specific cell types from adults with asthma that are stimulated by RSV. They also consider the role of early-life exposure to RSV and its contribution to asthma in adults. Lastly, they review the mechanisms by which RSV evades normal host immune responses and subverts these responses to its benefit.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966842 | PMC |
| http://dx.doi.org/10.1016/j.iac.2010.08.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Acute respiratory infections (ARIs) are a leading cause of death in children under five globally. The seasonal trends and profiles of respiratory viruses vary by region and season. Due to limited information and the population's vulnerability, we conducted the hospital-based surveillance of respiratory viruses in Eastern Uttar Pradesh.
View Article and Find Full Text PDFAVP-GPT2: A Transformer-Powered Platform for De Novo Generation, Screening, and Explanation of Antiviral Peptides.
Viruses
December 2024
Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd., Beijing 100176, China.
Human respiratory syncytial virus (RSV) remains a significant global health threat, particularly for vulnerable populations. Despite extensive research, effective antiviral therapies are still limited. To address this urgent need, we present AVP-GPT2, a deep-learning model that significantly outperforms its predecessor, AVP-GPT, in designing and screening antiviral peptides.
View Article and Find Full Text PDFAdvances and Challenges in Antiviral Development for Respiratory Viruses.
Pathogens
December 2024
Unidad de Investigación Biomédica de Zacatecas, Instituto Mexicano del Seguro Social, Zacatecas 98000, Mexico.
The development of antivirals for respiratory viruses has advanced markedly in response to the growing threat of pathogens such as Influenzavirus (IAV), respiratory syncytial virus (RSV), and SARS-CoV-2. This article reviews the advances and challenges in this field, highlighting therapeutic strategies that target critical stages of the viral replication cycle, including inhibitors of viral entry, replication, and assembly. In addition, innovative approaches such as inhibiting host cellular proteins to reduce viral resistance and repurposing existing drugs are explored, using advanced bioinformatics tools that optimize the identification of antiviral candidates.
View Article and Find Full Text PDFLower Airway Diseases in the Paediatric Population: A Two-Year, Single-Centre, Retrospective Study.
J Clin Med
January 2025
Department of Pediatric Emergency, Regina Margherita Children's Hospital, Città della Salute e della Scienza, 10126 Turin, Italy.
: Lower airway diseases in children are one of the major causes of hospitalisation. This study aimed to evaluate the characteristics of children admitted to a tertiary pediatric hospital diagnosed with lower airway disease and to identify differences between age groups and the two years of the study. : In this single-centre retrospective observational study, demographic and clinical information about children hospitalised in the emergency pediatric ward and diagnosed with lower respiratory disease from 1 June 2021 to 30 June 2023 were retrospectively reviewed.
View Article and Find Full Text PDFCharacteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine.
Medicina (Kaunas)
January 2025
Department of Health Sciences, University of Genoa, 16132 Genoa, Italy.
: Three respiratory syncytial virus (RSV) vaccines have been recently made available for older adults. Understanding the principal characteristics of the first vaccine-takers can pave the way for a successful vaccination campaign. The objective of this study was to explore the sociodemographic and clinical characteristics of the first Italian users of an adjuvanted RSV vaccine and their attitudes towards RSV and vaccination.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!